New Candida drug effective, with fewer ill effects

Article

-->

A new treatment for invasive candidosis and candidemia is as effective as liposomal amphotericin B but with fewer side effects, including fewer kidney function problems, researchers report online April 26 in The Lancet.

Ernst-Rudiger Kuse, MD, of the Klinik fur Viszeral und Transplantationschirurgie in Hannover, Germany, and colleagues compared results for 264 candidemia and invasive candidosis patients randomly treated with 100 mg daily of micafungin versus 267 patients given 3 mg/kg daily of liposomal amphotericin B.

After sorting cases according to neutropenia status at baseline, the researchers found a 0.7% difference in proportions. They also found that the two drugs' effectiveness did not depend on catheter status, number of blood neutrophils, main infection site, or other variables and adverse events were fewer with micafungin.

Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.

Related Videos
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
© 2024 MJH Life Sciences

All rights reserved.